Literature DB >> 7351290

Clinical features and prognosis of severe chronic active liver disease (CALD) after corticosteroid-induced remission.

A J Czaja, H V Ammon, W H Summerskill.   

Abstract

Disappearance of symptoms, resolution of most biochemical abnormalities, and histologic improvement to mild chronic inflammation were accomplished in 69 of 123 patients (56%) with severe chronic active liver disease treated with corticosteroids for up to 6.5 yr. Remission of at least 6 mo duration was possible in 35 of the 69 (51%) after discontinuation of therapy while others relapsed promptly and required retreatment. The likelihood of sustained remission was not predicted by initial clinical or biochemical features, although patients developing cirrhosis during treatment invariably relapsed. Subsequent courses of treatment after relapse were equally effective in again inducing remission, but the probability of another relapse increased after each successive therapy and was 86% after three treatments. Six of twenty-two patients (27%) followed for at least 4 yr after initial remission had three or more relapses. Although patients who relapsed were more likely to develop cirrhosis, manifestations of portal hypertension and immediate survival were not affected by relapse. Complete disappearance of all manifestations of active disease was possible in 12 of the patients entering remission (17%), but only patients without cirrhosis consistently sustained this improvement. We conclude that relapse after cessation of therapy frequently follows corticosteroid-induced remission of severe CALD, especially if cirrhosis develops, but does not jeopardize response to subsequent treatments or alter early prognosis.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7351290

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  19 in total

Review 1.  Emerging opportunities for site-specific molecular and cellular interventions in autoimmune hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2010-01-27       Impact factor: 3.199

2.  Drug-induced liver injury associated with Agaricus blazei Murill which is very similar to autoimmune hepatitis.

Authors:  Akiko Hisamochi; Masayoshi Kage; Teruko Arinaga; Tatsuya Ide; Ichiro Miyajima; Kei Ogata; Reiichiro Kuwahara; Yuriko Koga; Ryukichi Kumashiro; Michio Sata
Journal:  Clin J Gastroenterol       Date:  2013-02-05

3.  Diagnostic and prognostic implications of plasma amino acid determinations in chronic active hepatitis.

Authors:  M T Shiels; A J Czaja; J Ludwig; A J McCullough; J D Jones; V L Go
Journal:  Dig Dis Sci       Date:  1985-09       Impact factor: 3.199

4.  Late relapse of type 1 autoimmune hepatitis after corticosteroid withdrawal.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2010-04-29       Impact factor: 3.199

Review 5.  Difficult treatment decisions in autoimmune hepatitis.

Authors:  Albert J Czaja
Journal:  World J Gastroenterol       Date:  2010-02-28       Impact factor: 5.742

6.  Frequency and significance of phenotypes for alpha1-antitrypsin deficiency in type 1 autoimmune hepatitis.

Authors:  A J Czaja
Journal:  Dig Dis Sci       Date:  1998-08       Impact factor: 3.199

7.  Duration of chronic active hepatitis and the development of cirrhosis.

Authors:  A Vegnente; V F Larcher; A P Mowat; B Portmann; R Williams
Journal:  Arch Dis Child       Date:  1984-04       Impact factor: 3.791

Review 8.  Non-classical phenotypes of autoimmune hepatitis and advances in diagnosis and treatment.

Authors:  Albert J Czaja; Yusuf Bayraktar
Journal:  World J Gastroenterol       Date:  2009-05-21       Impact factor: 5.742

Review 9.  Drug therapy in the management of type 1 autoimmune hepatitis.

Authors:  A J Czaja
Journal:  Drugs       Date:  1999-01       Impact factor: 9.546

10.  Long-term treatment outcomes for autoimmune hepatitis in Korea.

Authors:  Jae Sook Kil; Joon Hyoek Lee; A-Reum Han; Ja Young Kang; Hye Jin Won; Han Young Jung; Hyun Min Lim; Geum-Youn Gwak; Moon Seok Choi; Kwang Cheol Koh; Seung Woon Paik; Byung Chul Yoo
Journal:  J Korean Med Sci       Date:  2009-12-29       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.